GW caps off top year with start of Phase III with Sativex in cancer pain
This article was originally published in Scrip
GW Pharmaceuticals, the cannabinoid-focused company, has capped off a strong year with an impressive set of results and the initiation of a Phase III programme in cancer pain for its lead product Sativex.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.